Seek Labs Maps 25 Viral Families with BioSeeker, Advancing a Sequence-Driven Model for Antiviral Discovery
Seek Labs, a private TechBio company focused on developing programmable platforms to decode, program, and ultimately resolve disease mechanisms, has announced a major scientific milestone in antiviral discovery. The company reports that it has successfully mapped CRISPR-addressable regions across all 25 viral families known to infect humans, creating what it describes as a comprehensive genomic atlas of viral vulnerabilities. This resource is intended to accelerate the identification of antiviral target sites across existing pathogens, emerging viral variants, and future outbreak threats.
The announcement reflects a broader shift in infectious disease research, where traditional antiviral development has largely remained reactive rather than predictive. Historically, when a new viral outbreak emerges, researchers must first sequence the pathogen, characterize its biology, identify druggable targets, and then initiate the long process of therapeutic or vaccine development. This timeline often stretches across years, leaving significant gaps in global preparedness during early outbreak stages.
Seek Labs is positioning its platform as a way to compress the earliest and most time-sensitive phase of this process: target identification. By pre-mapping viral genomes for CRISPR-accessible regions, the company aims to provide a pre-built framework that can guide rapid therapeutic design as soon as a pathogen is detected or re-emerges.
Building a Global Atlas of Viral Vulnerabilities
At the core of Seek Labs’ announcement is the creation of a CRISPR target atlas spanning all known human-infecting viral families. This atlas identifies regions within viral genomes that are suitable for CRISPR-based targeting, particularly those involved in viral replication and survival. These regions represent potential “genetic weak points” that can be exploited to disrupt viral function.
CRISPR-based antiviral strategies rely on programmable guide RNAs that direct molecular machinery to specific sequences in a pathogen’s genome. However, identifying optimal guide targets is often a time-consuming and computationally intensive process, especially when dealing with rapidly mutating viruses or newly emerging variants. By pre-mapping these regions across entire viral families, Seek Labs is attempting to reduce the time required to move from pathogen identification to therapeutic design.
The company states that its analysis covers 25 out of 25 viral families known to infect humans, effectively providing a comprehensive cross-family reference map. This allows researchers to not only identify targets for known pathogens but also to anticipate potential vulnerabilities in related or newly emerging viruses within the same family.
Addressing the Limitations of Reactive Antiviral Development
The need for faster antiviral response mechanisms is underscored by past outbreaks of high-consequence pathogens. In many cases, the global response to viral threats has been uneven, with effective countermeasures available for some strains but not others within the same viral family.
Seek Labs highlighted Ebola virus disease as a key example of this imbalance. For instance, Zaire ebolavirus has seen significant progress in countermeasure development, including the approval of an effective vaccine that has demonstrated clinical benefit in outbreak settings. This represents a success story in targeted vaccine development and shows that rapid scientific advancement can translate into meaningful public health impact when the right tools are available.
However, other related viruses, such as Bundibugyo virus, remain without similarly robust countermeasures. Despite belonging to the same broader viral genus, differences in genomic structure and immune evasion strategies have limited the effectiveness of existing approaches. This disparity highlights a key challenge in antiviral development: solutions are often highly strain-specific and may not translate across even closely related pathogens.
According to Douglas Gladue, PhD, a representative of Seek Labs, this gap illustrates the need for broader, more scalable antiviral strategies. He noted that while Zaire ebolavirus demonstrates the value of having effective interventions ready for deployment, Bundibugyo virus shows that closely related threats can still emerge outside the reach of current vaccines and therapies. He emphasized that Seek Labs’ platform is designed to support genus-level, pathogen-specific, and multiplexed antiviral discovery approaches.
A Platform Approach to CRISPR-Based Antiviral Discovery
Unlike traditional antiviral programs that focus on single pathogens or single drug candidates, Seek Labs is positioning its technology as a platform system. The CRISPR target atlas serves as a foundational dataset that can be applied across multiple viral families and therapeutic strategies.
By analyzing viral genomes at scale, the platform enables several key capabilities:
First, it allows researchers to identify candidate CRISPR guide regions within replication-essential viral sequences. These regions are particularly valuable because disrupting them may significantly impair the virus’s ability to replicate and spread within a host.
Second, the system enables prioritization of viral families and individual pathogens based on target density, accessibility, and biological relevance. This prioritization step is important for focusing experimental and therapeutic development efforts on the most promising or high-risk targets.
Third, the atlas supports the design of multiplexed CRISPR guide panels. Rather than relying on a single guide RNA to target a virus, multiplexing involves using multiple guides simultaneously to reduce the likelihood of viral escape through mutation. This strategy is especially important for RNA viruses, which are known for their high mutation rates.
Finally, the platform is designed to support the development of a scalable antiviral pipeline. By leveraging a shared computational and biological discovery engine, Seek Labs aims to streamline the transition from in silico target identification to laboratory validation and eventual therapeutic development.
From Computational Mapping to Experimental Validation
While the CRISPR target atlas represents a computational and bioinformatic milestone, Seek Labs emphasizes that the next stage of development involves experimental validation. The company plans to prioritize specific viral families and pathogens for further laboratory testing based on the atlas findings.
This validation process will include evaluation of target accessibility within viral genomes, assessment of guide RNA activity, measurement of impact on viral replication, and exploration of multiplexed targeting strategies. In addition, the company will incorporate in silico safety assessments to reduce the likelihood of off-target effects in human cells.
By integrating computational prediction with biological validation, Seek Labs aims to build a pipeline that can move from digital genome mapping to functional antiviral candidates more efficiently than traditional discovery workflows.
Implications for Future Pandemic Preparedness
The broader implications of Seek Labs’ work extend into global health preparedness and outbreak response strategy. One of the key challenges in infectious disease control is the speed at which new viral threats emerge compared to the speed at which countermeasures can be developed. This mismatch creates vulnerability windows during which outbreaks can spread before effective interventions are available.
A pre-mapped atlas of viral CRISPR target sites could help close this gap by enabling near-immediate identification of therapeutic candidates once a pathogen is sequenced. In theory, this could shift antiviral development from a reactive model to a more proactive or even anticipatory framework.
Rather than starting from scratch during each outbreak, researchers could begin with a pre-existing map of validated or predicted viral vulnerabilities, significantly reducing early-stage discovery timelines.
Expanding the Scope of Programmable Medicine
Seek Labs’ approach reflects a broader trend in biotechnology toward programmable medicine, where biological systems are engineered using modular and computationally designed tools. CRISPR technology has already transformed genetic engineering and diagnostics, and its application in antiviral therapeutics represents an emerging frontier.
By combining large-scale genomic mapping with CRISPR-based targeting strategies, the company is attempting to create a unified framework for addressing viral diseases across multiple families. If successful, this platform approach could potentially be extended beyond antivirals to other classes of disease, including bacterial infections, genetic disorders, and even complex multi-factorial conditions.
With its announcement of a comprehensive CRISPR-addressable viral atlas spanning all known human-infecting viral families, Seek Labs is positioning itself at the intersection of computational biology, gene editing, and infectious disease preparedness. The company’s platform aims to transform antiviral discovery from a reactive, pathogen-by-pathogen process into a scalable, pre-mapped system for rapid therapeutic design.
By identifying conserved and replication-critical viral regions across 25 viral families, Seek Labs is laying the groundwork for faster, more flexible, and potentially more resilient antiviral development strategies. As the company moves toward experimental validation and therapeutic design, its work could play a role in reshaping how the global scientific community responds to both current and future viral threats.
About BioSeeker
BioSeeker is Seek Labs’ AI-powered discovery engine designed to analyze thousands of sequences to identify the regions a pathogen cannot mutate without losing essential function. By focusing on these functionally critical regions, BioSeeker identifies durable targets for intervention, producing outputs that power the company’s platforms across Sequence Ablation Therapeutics and molecular diagnostics. As new sequence data emerges, BioSeeker continuously updates its models, providing a dynamic foundation for programmable, sequence-directed discovery.
About Seek Labs
Every disease has a sequence. Seek Labs is a TechBio company building the systems to decode, program, and resolve diseases. At the core of this system is an AI-powered intelligence layer that analyzes and translates sequences into actionable data, informing two deployment layers across Sequence Ablation Therapeutics (SAT) and molecular detection. Together, these systems form a continuous loop where genomic data is decoded, translated into therapeutic and diagnostic outputs, and refined through real-world deployment.
Headquartered in Salt Lake City, Seek Labs is a proud member of BioHive, Utah’s collaborative life sciences ecosystem. Together with our partners, we’re building faster, smarter solutions for the world’s most urgent health challenges.
